Karyopharm director granted 15,508 RSUs

Karyopharm Therapeutics Inc. director Garen G. Bohlin received an award of 15,508 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan.

Rhea-AI Filing Summary

Karyopharm Therapeutics Inc. director Garen G. Bohlin received an award of 15,508 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan. These RSUs will vest 100% on May 21, 2027 and convert into common stock on a one-for-one basis.

Delivery of the vested shares is deferred until the earlier of the director’s separation from service or a change-in-control event. Following this grant, Bohlin holds 18,517 shares of common stock. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.

Insider Trade Summary

Grant/Award: 15,508 shares

Grant/Award 1 txn

Insider BOHLIN GAREN G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,508	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,517 shares (Direct)

Footnotes (2)

1. F1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.
2. F2. Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

Key Figures

RSU grant size: 15,508 RSUs Vesting date: May 21, 2027 Post-transaction holdings: 18,517 shares +2 more

5 metrics

RSU grant size 15,508 RSUs Awarded to director Garen G. Bohlin on May 21, 2026

Vesting date May 21, 2027 RSUs vest 100% on this date

Post-transaction holdings 18,517 shares Total common stock held after RSU award

Reverse split ratio 1-for-15 Reverse stock split effective February 25, 2025

Transaction price per share $0.00 per share RSU grant, no cash consideration reported

Key Terms

restricted stock units ("RSUs"), 2022 Equity Incentive Plan, change-in-control event, reverse stock split

4 terms

restricted stock units ("RSUs") financial

"Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2022 Equity Incentive Plan financial

"pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended"

change-in-control event financial

"delivery of the shares is deferred until the earlier of the director's separation from service and a change-in-control event"

reverse stock split financial

"reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm Therapeutics (KPTI) disclose about director Garen Bohlin?

Karyopharm Therapeutics disclosed that director Garen G. Bohlin received 15,508 restricted stock units (RSUs) as equity compensation. These RSUs convert into common stock on a one-for-one basis and increase his total reported holdings to 18,517 shares after the transaction.

How many KPTI RSUs were granted to Garen Bohlin and when do they vest?

Garen G. Bohlin was granted 15,508 restricted stock units (RSUs) of Karyopharm Therapeutics. The RSUs vest 100% on May 21, 2027, providing a long-term equity incentive that aligns his compensation with the company’s future performance over multiple years.

When will Garen Bohlin receive the KPTI shares from his RSU award?

Bohlin will receive the Karyopharm Therapeutics shares only after vesting and a deferral condition. Delivery occurs at the earlier of his separation from service with Karyopharm or a change-in-control event, meaning he does not immediately obtain the underlying common stock.

How many Karyopharm Therapeutics shares does Garen Bohlin hold after this Form 4?

After the reported RSU grant, Garen G. Bohlin is shown holding 18,517 shares of Karyopharm Therapeutics common stock. This figure includes the impact of the one-for-fifteen reverse stock split the company implemented on February 25, 2025, as noted in the filing.

What is the impact of Karyopharm’s reverse stock split on this Form 4 data?

All share amounts in the Form 4, including the 15,508 RSUs and 18,517 total shares held, reflect Karyopharm’s one-for-fifteen reverse stock split. The split, effective February 25, 2025, consolidated every fifteen pre-split shares into one post-split share.

What plan governs the RSU grant to Karyopharm director Garen Bohlin?

The RSU grant to Garen G. Bohlin was made under the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. This plan provides equity-based awards like restricted stock units to align directors’ and employees’ interests with long-term shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/26/2026 - 04:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOHLIN GAREN G

(Last) (First) (Middle)

C/O KARYOPHARM THERAPEUTICS INC.

85 WELLS AVENUE

(Street)

NEWTON MASSACHUSETTS 02459

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Karyopharm Therapeutics Inc. [ KPTI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/21/2026		A		15,508(1)	A	$0	18,517(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on May 21, 2027; however, delivery of the shares is deferred until the earlier of (a) the date of the director's separation from service to Karyopharm Therapeutics Inc. and (b) a change-in-control event.

2. Amounts reported in this Form 4 reflect the one-for fifteen reverse stock split effected by Karyopharm Therapeutics Inc. on February 25, 2025.

	/s/ Nancy Smith, Attorney-in-Fact for Garen Bohlin	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)